WO2011068403A3 - Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts - Google Patents

Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts Download PDF

Info

Publication number
WO2011068403A3
WO2011068403A3 PCT/NL2010/050809 NL2010050809W WO2011068403A3 WO 2011068403 A3 WO2011068403 A3 WO 2011068403A3 NL 2010050809 W NL2010050809 W NL 2010050809W WO 2011068403 A3 WO2011068403 A3 WO 2011068403A3
Authority
WO
WIPO (PCT)
Prior art keywords
salts
ethynylphenylamino
methoxyethoxy
bis
novel
Prior art date
Application number
PCT/NL2010/050809
Other languages
French (fr)
Other versions
WO2011068403A2 (en
Inventor
Evanthia Dova
Samir Kulkarni
Marcel Hoffmann
Mihaela Maria Pop
Original Assignee
Ultimorphix Technologies B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultimorphix Technologies B.V. filed Critical Ultimorphix Technologies B.V.
Publication of WO2011068403A2 publication Critical patent/WO2011068403A2/en
Publication of WO2011068403A3 publication Critical patent/WO2011068403A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel ethanesulfonate, isethionate, bromide, malonate, L-lactate, and succinate salts and polymorphs thereof of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine (Erlotinib). The invention also relates to pharmaceutical compositions containing Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate, succinate salts and to the methods of treating hyperproliferative disorders such as cancer, by administering the Erlotinib salts.
PCT/NL2010/050809 2009-12-02 2010-12-02 Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts WO2011068403A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26588809P 2009-12-02 2009-12-02
US61/265,888 2009-12-02
US26628209P 2009-12-03 2009-12-03
US61/266,282 2009-12-03

Publications (2)

Publication Number Publication Date
WO2011068403A2 WO2011068403A2 (en) 2011-06-09
WO2011068403A3 true WO2011068403A3 (en) 2011-09-15

Family

ID=43533387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2010/050809 WO2011068403A2 (en) 2009-12-02 2010-12-02 Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts

Country Status (1)

Country Link
WO (1) WO2011068403A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230483B1 (en) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib salts
CN102584719A (en) * 2012-02-02 2012-07-18 瑞阳制药有限公司 Preparing technology of erlotinib hydrochloride
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN113880897B (en) * 2020-10-30 2023-06-02 杭州拉林智能科技有限公司 Flavonoid glycoside-organic amine tyrosine kinase inhibitor double salt compound and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122776A2 (en) * 2007-04-04 2008-10-16 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
JP2003518485A (en) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク Pharmaceutical composition giving improved drug concentration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122776A2 (en) * 2007-04-04 2008-10-16 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts

Also Published As

Publication number Publication date
WO2011068403A2 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
MX2014002836A (en) Aminopyrimidine derivatives for use as modulators of kinase activity.
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
EA023222B8 (en) Pyrazolyl quinazoline kinase inhibitors
WO2013163190A8 (en) Dna-pk inhibitors
MX2012001419A (en) Novel bicyclic urea compounds.
EA201391470A1 (en) SUBSTITUTED SALTS 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE
MX353806B (en) Quinolines as fgfr kinase modulators.
WO2010054285A3 (en) Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
WO2013049726A3 (en) Processes for making compounds useful as inhibitors of atr kinase
GEP20156239B (en) Benzofuranyl derivatives used as glucokinase inhibitors
AU2011278832A8 (en) Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
WO2012013282A8 (en) Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
MX2011012337A (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases.
WO2013173441A3 (en) Enhancer of zeste homolog 2 inhibitors
MX2013005008A (en) Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands.
MX2014005928A (en) Heterocyclic inhibitors of glutaminase.
EA201290515A1 (en) AMINOPYRIMIDINES AS SYK INHIBITORS
MY160468A (en) Novel amino azaheterocyclic carboxamides
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MX2012013082A (en) 2 -aminopyridine derivatives useful as inhibitors of atr kinase.
WO2011082266A3 (en) Substituted heterocyclic compounds
EA201500182A1 (en) 4-METHYL-2,3,5,9,9b-PENTAASACYCLOPENT [a] NAFTAIL
MX2013005751A (en) Quinazoline carboxamide azetidines.
MX2012001413A (en) Novel azaheterocyclic compounds.
TW200621728A (en) Pyrimidine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10798633

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10798633

Country of ref document: EP

Kind code of ref document: A2